Effectiveness and safety of the Space GlucoseControl system for glycaemia control in caring for postoperative cardiac surgical patients

Hyperglycaemia is a very common complication in post–cardiac surgical patients, and as such, it must be properly managed. For this purpose, the enhanced Model Predictive Control algorithm for glycaemia control has been implemented into a nurse-led device called Space GlucoseControl (SGC) that aims t...

Full description

Saved in:
Bibliographic Details
Published in:Australian critical care 2022-03, Vol.35 (2), p.136-142
Main Authors: González-Caro, María-Dolores, Fernández-Castillo, Rafael-Jesús, Carmona-Pastor, Marta, Arroyo-Muñoz, Francisco-Javier, González-Fernández, Francisco-Javier, Garnacho-Montero, José
Format: Article
Language:English
Subjects:
Adult
Blood Glucose
Cardiac surgical procedures
Critical care nursing
Glycaemia control
Glycemic Control
Healthcare technology
Humans
Hyperglycemia
Hypoglycemic Agents
Insulin
Postoperative Period
Prospective Studies
SpaceGlucose control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperglycaemia is a very common complication in post–cardiac surgical patients, and as such, it must be properly managed. For this purpose, the enhanced Model Predictive Control algorithm for glycaemia control has been implemented into a nurse-led device called Space GlucoseControl (SGC) that aims to achieve a safe and effective blood glucose control in a better way than the traditional “paper-based” protocols. The aim of the study was to know the effectiveness and safety of the SGC in glycaemia control in cardiosurgical adult patients in the immediate postoperative period in the intensive care unit. A prospective before-and-after intervention study was conducted. One hundred sixty cardiosurgical adult patients with hyperglycaemia were selected: 80 in the control group from May to November 2018 and 80 in the intervention group (use of the SGC device) from January to December 2019. The primary outcome was the percentage of time within the target range (140–180 mg/dL in the control group and 100–160 mg/dL in the intervention group). The percentage of time within the target range was significantly higher in the SGC group than in the control group (70.5% [58.25–80] vs 54.83% [36.09–75], p 
ISSN:1036-7314
1878-1721
DOI:10.1016/j.aucc.2021.03.001